HK1120417A1 - Stable nanoparticle formulations - Google Patents

Stable nanoparticle formulations

Info

Publication number
HK1120417A1
HK1120417A1 HK08112250.2A HK08112250A HK1120417A1 HK 1120417 A1 HK1120417 A1 HK 1120417A1 HK 08112250 A HK08112250 A HK 08112250A HK 1120417 A1 HK1120417 A1 HK 1120417A1
Authority
HK
Hong Kong
Prior art keywords
nanoparticle formulations
stable nanoparticle
formulations
stable
processes
Prior art date
Application number
HK08112250.2A
Other languages
English (en)
Inventor
Khawla Abdullah Abu-Izza
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of HK1120417A1 publication Critical patent/HK1120417A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08112250.2A 2005-05-05 2008-11-07 Stable nanoparticle formulations HK1120417A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67808605P 2005-05-05 2005-05-05
PCT/US2006/017059 WO2007086911A2 (fr) 2005-05-05 2006-05-03 Formulations nanoparticulaires stables

Publications (1)

Publication Number Publication Date
HK1120417A1 true HK1120417A1 (en) 2009-04-03

Family

ID=38309654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112250.2A HK1120417A1 (en) 2005-05-05 2008-11-07 Stable nanoparticle formulations

Country Status (16)

Country Link
US (1) US20080038359A1 (fr)
EP (1) EP1895982A2 (fr)
JP (1) JP5483874B2 (fr)
KR (2) KR20080015077A (fr)
CN (1) CN101252914B (fr)
AU (2) AU2006336414B2 (fr)
BR (1) BRPI0611433A2 (fr)
CA (1) CA2606861C (fr)
HK (1) HK1120417A1 (fr)
IL (1) IL187128A0 (fr)
MA (1) MA29492B1 (fr)
NO (1) NO20076120L (fr)
NZ (1) NZ562559A (fr)
RU (1) RU2409352C2 (fr)
WO (1) WO2007086911A2 (fr)
ZA (1) ZA200708633B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923478B2 (en) * 2006-12-28 2011-04-12 Bridgestone Corporation Nanoporous polymeric material and preparation method
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2013041944A1 (fr) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Procédé pour la préparation de candésartan cilexétil micronisé
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
SG11201808799SA (en) * 2016-04-15 2018-11-29 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263310A (en) * 1974-03-02 1981-04-21 Boehringer Ingelheim Gmbh 8-Bromo-6-(o-chloro-phenyl)-4H-S-triazolo-[3,4,-c]-thieno-[2,3-e]-1,4-diazepines and salts thereof
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
CA2019719A1 (fr) * 1990-06-25 1991-12-25 William J. Thompson Bain de bouche
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
JPH05305226A (ja) * 1992-04-28 1993-11-19 Takeda Chem Ind Ltd 粒子及びその製造法
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ES2194477T3 (es) * 1998-06-19 2003-11-16 Skyepharma Canada Inc Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1239844B1 (fr) * 1999-12-20 2005-06-08 Nicholas J. Kerkhof Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
FR2813306B1 (fr) * 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
US7105176B2 (en) * 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
KR20030059318A (ko) * 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
EP1455730A4 (fr) * 2001-12-06 2006-01-18 Ranbaxy Lab Ltd Compositions d'isotretinoine nanoparticulaire
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
CN1310648C (zh) * 2002-12-13 2007-04-18 佳高泰克有限公司 局部纳米颗粒螺甾内酯制剂
DE50312980D1 (de) * 2003-05-07 2010-09-23 Kemira Pigments Oy Ftstoffen und aromen
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법

Also Published As

Publication number Publication date
RU2409352C2 (ru) 2011-01-20
WO2007086911A2 (fr) 2007-08-02
MA29492B1 (fr) 2008-05-02
KR20140002810A (ko) 2014-01-08
IL187128A0 (en) 2008-06-05
RU2007145055A (ru) 2009-06-10
CN101252914B (zh) 2013-03-27
WO2007086911A3 (fr) 2008-04-17
AU2006336414B2 (en) 2011-11-24
JP2008540439A (ja) 2008-11-20
JP5483874B2 (ja) 2014-05-07
CN101252914A (zh) 2008-08-27
US20080038359A1 (en) 2008-02-14
BRPI0611433A2 (pt) 2010-09-08
AU2006336414A1 (en) 2007-08-02
ZA200708633B (en) 2009-01-28
CA2606861C (fr) 2012-08-07
EP1895982A2 (fr) 2008-03-12
NZ562559A (en) 2011-03-31
KR20080015077A (ko) 2008-02-18
AU2010241245A1 (en) 2010-11-25
NO20076120L (no) 2007-11-27
CA2606861A1 (fr) 2007-08-02

Similar Documents

Publication Publication Date Title
TW200716646A (en) (S)-N-methylnaltrexone
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
IL183274A0 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
UA96449C2 (en) Stable laquinimod preparations
WO2007027941A3 (fr) Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
WO2006099169A3 (fr) Nouvelles compositions de liposomes
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
HK1118011A1 (zh) 透明質酸的抗腫瘤生物結合物或以化學接合方法間接地取得的衍生物，以及其製藥用途
EP2007398A4 (fr) Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées
TNSN08284A1 (en) Masking the taste of powders
WO2009121039A3 (fr) Administration de compositions de benzodiazépine
WO2010021607A3 (fr) Préparation pharmaceutique
WO2006002077A3 (fr) Formulations pharmaceutiques stables de composes de benzimidazole
WO2008030818A3 (fr) Nouvelles compositions de liposomes
HK1120417A1 (en) Stable nanoparticle formulations
WO2009084036A3 (fr) Composition utilisée pour traiter les infections virales
MXPA05008902A (es) Soluciones de drogas en mentol.
WO2008004100A3 (fr) Composés thérapeutiques
MX2009005804A (es) Composicion farmaceutica de memantina.
WO2008001294A3 (fr) Compositions pharmaceutiques pour l'administration orale à des doses élévées d'arteméther et de luméfantrine
WO2007071721A3 (fr) Extrait de gingembre pour inhiber des transporteurs de medicament humains
GB0620619D0 (en) Novel compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170503